These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27344734)

  • 21. Is it time for everolimus-based combination in castration-resistant prostate cancer?
    Roviello G; Ravelli A; Barni S; Petrelli F; Bottini A; Fox SB; Generali D
    Future Oncol; 2016 Aug; 12(16):1849-52. PubMed ID: 27250597
    [No Abstract]   [Full Text] [Related]  

  • 22. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 23. Olaparib Targets Some Advanced Prostate Cancers.
    Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
    Dreicer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-5. PubMed ID: 26352772
    [No Abstract]   [Full Text] [Related]  

  • 25. [Docetaxel chemotherapy against CRPC].
    Nagao K; Matsuyama H
    Nihon Rinsho; 2016 May; 74 Suppl 3():619-23. PubMed ID: 27344805
    [No Abstract]   [Full Text] [Related]  

  • 26. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
    [No Abstract]   [Full Text] [Related]  

  • 28. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.
    Al-Asaaed S; Winquist E
    Curr Oncol Rep; 2013 Apr; 15(2):113-8. PubMed ID: 23266703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.
    Aziz A; Kempkensteffen C; May M; Lebentrau S; Burger M; Chun FK; Brookman-May S
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):649-66. PubMed ID: 25905802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies.
    Kim W; Ryan CJ
    J Comp Eff Res; 2016 Jan; 5(1):5-7. PubMed ID: 26690748
    [No Abstract]   [Full Text] [Related]  

  • 33. [Chemotherapy for CRPC].
    Ozono S; Furuse H
    Nihon Rinsho; 2014 Dec; 72(12):2170-3. PubMed ID: 25518353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging agents for the therapy of advanced prostate cancer.
    Hathaway AR; Baker MK; Sonpavde G
    Future Oncol; 2015; 11(20):2775-87. PubMed ID: 26367474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antisense oligonucleotide therapy for patients with castration-resistant prostate cancer].
    Muramaki M; Miyake H; Fujisawa M
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():170-3. PubMed ID: 22207965
    [No Abstract]   [Full Text] [Related]  

  • 37. [Corticotherapy in castration-resistant prostate cancer].
    Lebdai S; Branchereau J; Robert G; De La Taille A; Bouchaert P
    Prog Urol; 2013 Oct; 23 Suppl 1():S23-33. PubMed ID: 24314736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
    Schutz FA; Buzaid AC; Sartor O
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).
    Georgi B; Korzeniewski N; Hadaschik B; Grüllich C; Roth W; Sültmann H; Pahernik S; Hohenfellner M; Duensing S
    Int J Oncol; 2014 Oct; 45(4):1337-44. PubMed ID: 25070358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
    Zustovich F; Fabiani F
    Crit Rev Oncol Hematol; 2014 Aug; 91(2):197-209. PubMed ID: 24503416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.